Valo Therapeutics

Valo Therapeutics is an immunotherapy company developing antigen-coated oncolytic viruses and vaccine vectors as therapeutic vaccines for cancer and infectious diseases. Valo Tx's lead platform, PeptiCRAd (peptide-coated conditionally replicating adenovirus), was developed in the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. It converts oncolytic adenoviruses into tissue-targeted specific cancer vaccines without the need to generate and manufacture multiple transgenic viruses. The company is also collaborating with Professor Cerullo to develop PeptiENV, PeptiVAX, and other neoantigen strategies. PeptiENV is expected to enhance the therapeutic response to oncolytic enveloped viruses in the treatment of various cancers.